J. Adachi

Discrimination of changes in osteoporosis outcomes.

P. Tugwell, V. Welch, B. Shea, 2001, The Journal of rheumatology.

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada

R. Goeree, G. Ioannidis, D. Chau, 2012, Journal of medical economics.

Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers

C. Kovacs, D. Goltzman, C. Berger, 2015, Clinical endocrinology.

Longitudinal assessment of health-related quality of life in osteoporosis: data from the population-based Canadian Multicentre Osteoporosis Study

D. Goltzman, C. Berger, T. Anastassiades, 2019, Osteoporosis International.

Comparison of Speed of Sound Measures Assessed by Multisite Quantitative Ultrasound to Bone Mineral Density Measures Assessed by Dual-Energy X-Ray Absorptiometry in a Large Canadian Cohort: the Canadian Multicentre Osteoporosis Study (CaMos).

Jacques P. Brown, D. Hanley, K. Davison, 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos

W. Leslie, C. Kovacs, G. Ioannidis, 2011, Osteoporosis International.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

I. Reid, R. Eastell, N. Watts, 2004, Archives of internal medicine.

Development and validation of the fracture risk scale home care (FRS-HC) that predicts one-year incident fracture: an electronic record-linked longitudinal cohort study

J. Hirdes, L. Giangregorio, G. Ioannidis, 2020, BMC Musculoskeletal Disorders.